2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract

Metastatic castration-resistant prostate cancer (mCRPC) presents significant treatment challenges. Although androgen deprivation therapy (ADT) has been the standard treatment for metastatic prostate cancer for over 80 years, its efficacy is often limited to the initial treatment phase for most patients.

A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract



Ray Manneh, MD, Sociedad de Oncologia y Hematologia del Cesar, Genitourinary Cancer, Valledupar, Colombia

Read the Abstract